MX2009010082A - Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. - Google Patents
Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma.Info
- Publication number
- MX2009010082A MX2009010082A MX2009010082A MX2009010082A MX2009010082A MX 2009010082 A MX2009010082 A MX 2009010082A MX 2009010082 A MX2009010082 A MX 2009010082A MX 2009010082 A MX2009010082 A MX 2009010082A MX 2009010082 A MX2009010082 A MX 2009010082A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- same
- substituted isoindoline
- isoindoline derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
Abstract
Se proporcionan compuestos de isoindolina 4'-O sustituida de la fórmula (l), y sales farmacéuticamente aceptables, solvatos, clatratos, estereoisómeros y profármacos de los mismos. Se describen métodos de uso y composiciones farmacéuticas de estos compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91932307P | 2007-03-20 | 2007-03-20 | |
PCT/US2008/003602 WO2008115516A2 (en) | 2007-03-20 | 2008-03-19 | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009010082A true MX2009010082A (es) | 2009-10-19 |
Family
ID=39719168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009010082A MX2009010082A (es) | 2007-03-20 | 2008-03-19 | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. |
Country Status (25)
Country | Link |
---|---|
US (6) | US8153659B2 (es) |
EP (2) | EP3101017B1 (es) |
JP (4) | JP2010522170A (es) |
KR (3) | KR101791757B1 (es) |
CN (2) | CN103641814A (es) |
AR (1) | AR065810A1 (es) |
AU (1) | AU2008229383B2 (es) |
BR (1) | BRPI0809011A8 (es) |
CA (1) | CA2681633C (es) |
CL (1) | CL2008000805A1 (es) |
CO (1) | CO6231033A2 (es) |
CR (2) | CR11036A (es) |
EC (1) | ECSP099663A (es) |
ES (2) | ES2734253T3 (es) |
IL (1) | IL200990A (es) |
MX (1) | MX2009010082A (es) |
MY (1) | MY180812A (es) |
NI (1) | NI200900170A (es) |
NZ (2) | NZ599199A (es) |
PE (1) | PE20081894A1 (es) |
RU (1) | RU2471794C2 (es) |
UA (1) | UA97976C2 (es) |
UY (1) | UY30977A1 (es) |
WO (1) | WO2008115516A2 (es) |
ZA (1) | ZA200906497B (es) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2929331B2 (ja) * | 1990-07-18 | 1999-08-03 | 丸善石油化学株式会社 | トラクションドライブ用流体 |
WO2006060507A2 (en) * | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
EP3101017B1 (en) * | 2007-03-20 | 2019-06-12 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
US7964354B2 (en) | 2007-12-20 | 2011-06-21 | Celgene Corporation | Use of micro-RNA as a biomarker of immunomodulatory drug activity |
CA2781888C (en) * | 2009-12-11 | 2019-06-18 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
LT3202460T (lt) * | 2010-02-11 | 2019-10-10 | Celgene Corporation | Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus |
AU2016203826B2 (en) * | 2010-02-11 | 2018-05-17 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
AU2013245487B2 (en) * | 2010-02-11 | 2016-03-10 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
EP2720695A4 (en) | 2011-06-15 | 2014-11-12 | Nono Inc | ACTIVE AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES |
CN102731850B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油耐磨橡胶 |
CN102731851B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 一种耐油橡胶 |
CN102731853B (zh) * | 2012-06-28 | 2013-11-27 | 芜湖宏达橡塑阀门制造有限公司 | 耐油橡胶 |
ES2755748T3 (es) * | 2012-07-27 | 2020-04-23 | Celgene Corp | Procedimientos para preparar compuestos de isoindolin-1,3-diona |
WO2014025978A1 (en) | 2012-08-09 | 2014-02-13 | Celgene Corporation | Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof |
NZ628077A (en) | 2012-08-09 | 2017-04-28 | Celgene Corp | Treatment of immune-related and inflammatory diseases |
EP3949968A1 (en) * | 2012-08-09 | 2022-02-09 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
CA2935495C (en) | 2013-01-14 | 2021-04-20 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
US9242966B2 (en) | 2013-03-11 | 2016-01-26 | Bristol-Myers Squibb Company | Phthalazines as potassium ion channel inhibitors |
CA2941560A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
KR102223060B1 (ko) | 2013-04-17 | 2021-03-05 | 시그날 파마소티칼 엘엘씨 | 암 치료를 위한 TOR 키나제 억제제 및 IMiD 화합물을 포함하는 조합요법 |
UA117141C2 (uk) | 2013-10-08 | 2018-06-25 | Селджин Корпорейшн | Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
TWI745271B (zh) | 2014-05-19 | 2021-11-11 | 美商西建公司 | 全身紅斑性狼瘡之治療 |
PL3214081T3 (pl) * | 2014-10-30 | 2021-04-06 | Kangpu Biopharmaceuticals, Ltd. | Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
US10159665B2 (en) | 2016-03-23 | 2018-12-25 | Louis Habash | Preventing amyloid plaque formation by treating a human subject with a nitroxide |
US20180078539A1 (en) | 2016-03-23 | 2018-03-22 | Louis Habash | T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide |
JP2019509352A (ja) * | 2016-03-23 | 2019-04-04 | ルイス ハバシュ, | ヒトの被験物質をニトロキシドで処理することによってapoptosis関連遺伝子の発現レベルを増加させる |
US10231959B2 (en) | 2016-03-23 | 2019-03-19 | Louis Habash | Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
ES2884064T3 (es) * | 2016-12-16 | 2021-12-10 | Kangpu Biopharmaceuticals Ltd | Composición combinada que comprende un compuesto benzoheterocíclico y un modulador de la vía de los receptores androgénicos y usos de la misma |
WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS |
EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
KR102548191B1 (ko) * | 2018-04-09 | 2023-06-28 | 상하이테크 유니버시티 | 표적 단백질 분해 화합물, 이의 항종양 응용, 이의 중간체 및 중간체의 응용 |
EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | SPIROCYCLIC COMPOUNDS |
CA3096404A1 (en) | 2018-04-23 | 2019-10-31 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
WO2020012334A1 (en) * | 2018-07-10 | 2020-01-16 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
CN110963994B (zh) * | 2018-09-30 | 2022-02-08 | 中国科学院上海药物研究所 | 异吲哚啉类化合物、其制备方法、药物组合物及用途 |
JP7466549B2 (ja) | 2018-10-01 | 2024-04-12 | セルジーン コーポレイション | がん治療のための併用療法 |
US20220001018A1 (en) * | 2018-11-01 | 2022-01-06 | Northwestern University | Targeting pleckstrin-2 for treating cancer |
WO2020114482A1 (zh) | 2018-12-06 | 2020-06-11 | 中国科学院上海药物研究所 | 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用 |
US20220168217A1 (en) * | 2019-02-22 | 2022-06-02 | Elkem Silicones USA Corp. | Drug delivery silicone composition to improve active ingredient elution |
CN111747924B (zh) * | 2019-03-29 | 2023-11-10 | 华东师范大学 | 一类来那度胺/泊马度胺类似物及其应用 |
CA3130469A1 (en) | 2019-04-12 | 2020-10-15 | C4 Therapeutics, Inc. | Tricyclic degraders of ikaros and aiolos |
TWI762939B (zh) | 2019-05-31 | 2022-05-01 | 大陸商海思科醫藥集團股份有限公司 | Btk抑制劑環衍生物及其製備方法和藥學上的應用 |
KR20220145366A (ko) * | 2020-02-25 | 2022-10-28 | 상하이테크 유니버시티 | 글루타르이미드 골격을 기초로 하는 화합물 및 그 응용 |
JP2023523545A (ja) * | 2020-04-17 | 2023-06-06 | エサイエント ファーマシューティカルズ,インコーポレイティド | Mas関連Gタンパク質受容体X4のモジュレーター、関連製品及びその使用方法 |
WO2022017365A1 (zh) | 2020-07-20 | 2022-01-27 | 江苏恒瑞医药股份有限公司 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
WO2022148358A1 (zh) * | 2021-01-05 | 2022-07-14 | 江苏恒瑞医药股份有限公司 | 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用 |
WO2022152821A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
WO2023138647A1 (zh) * | 2022-01-19 | 2023-07-27 | 江苏恒瑞医药股份有限公司 | 一种含硫异吲哚啉类衍生物的晶型 |
WO2024097932A1 (en) * | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Compounds and their use for treatment of hemoglobinopathies |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5001116A (en) | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
KR19980074060A (ko) * | 1997-03-21 | 1998-11-05 | 김윤배 | 신규한 치환된 3,4-디알콕시페닐 유도체 |
DK1064277T3 (da) * | 1998-03-16 | 2005-10-17 | Celgene Corp | 2-(2,6-dioxopiperidin-3-yl)isoindolinderivater, deres fremstilling og deres anvendelse som inhibitorer af inflammatoriske cytokiner |
US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
EP1663223B1 (en) * | 2003-09-17 | 2014-01-01 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Thalidomide analogs as tnf-alpha modulators |
GB0324790D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
WO2006060507A2 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
MY140868A (en) * | 2004-12-24 | 2010-01-29 | Astrazeneca Ab | Amide derivatives |
EP3101017B1 (en) * | 2007-03-20 | 2019-06-12 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
-
2008
- 2008-03-19 EP EP16170365.7A patent/EP3101017B1/en active Active
- 2008-03-19 CN CN201310547773.7A patent/CN103641814A/zh active Pending
- 2008-03-19 JP JP2009554563A patent/JP2010522170A/ja not_active Withdrawn
- 2008-03-19 AR ARP080101179A patent/AR065810A1/es not_active Application Discontinuation
- 2008-03-19 ES ES16170365T patent/ES2734253T3/es active Active
- 2008-03-19 BR BRPI0809011A patent/BRPI0809011A8/pt not_active Application Discontinuation
- 2008-03-19 NZ NZ599199A patent/NZ599199A/xx not_active IP Right Cessation
- 2008-03-19 WO PCT/US2008/003602 patent/WO2008115516A2/en active Application Filing
- 2008-03-19 ES ES08726977.5T patent/ES2601131T3/es active Active
- 2008-03-19 KR KR1020157009558A patent/KR101791757B1/ko active IP Right Grant
- 2008-03-19 EP EP08726977.5A patent/EP2142534B1/en active Active
- 2008-03-19 US US12/077,715 patent/US8153659B2/en active Active
- 2008-03-19 RU RU2009138500/04A patent/RU2471794C2/ru active
- 2008-03-19 KR KR1020097021797A patent/KR20090121400A/ko active Application Filing
- 2008-03-19 AU AU2008229383A patent/AU2008229383B2/en active Active
- 2008-03-19 MX MX2009010082A patent/MX2009010082A/es active IP Right Grant
- 2008-03-19 CN CN200880016715A patent/CN101679380A/zh active Pending
- 2008-03-19 KR KR1020177021704A patent/KR20170093996A/ko not_active Application Discontinuation
- 2008-03-19 MY MYPI20093935A patent/MY180812A/en unknown
- 2008-03-19 NZ NZ579890A patent/NZ579890A/en not_active IP Right Cessation
- 2008-03-19 UA UAA200910592A patent/UA97976C2/ru unknown
- 2008-03-19 CA CA2681633A patent/CA2681633C/en active Active
- 2008-03-20 CL CL2008000805A patent/CL2008000805A1/es unknown
- 2008-03-24 UY UY30977A patent/UY30977A1/es not_active Application Discontinuation
- 2008-03-24 PE PE2008000525A patent/PE20081894A1/es not_active Application Discontinuation
-
2009
- 2009-09-16 IL IL200990A patent/IL200990A/en not_active IP Right Cessation
- 2009-09-17 ZA ZA2009/06497A patent/ZA200906497B/en unknown
- 2009-09-18 NI NI200900170A patent/NI200900170A/es unknown
- 2009-09-21 CR CR11036A patent/CR11036A/es unknown
- 2009-09-30 CO CO09106869A patent/CO6231033A2/es not_active Application Discontinuation
- 2009-09-30 EC EC2009009663A patent/ECSP099663A/es unknown
-
2012
- 2012-03-01 US US13/410,216 patent/US8614328B2/en not_active Ceased
-
2013
- 2013-11-18 US US14/083,205 patent/US9181216B2/en active Active
-
2014
- 2014-06-25 JP JP2014129790A patent/JP5927241B2/ja active Active
- 2014-07-16 US US14/333,454 patent/USRE46639E1/en active Active
- 2014-08-01 CR CR20140368A patent/CR20140368A/es unknown
-
2015
- 2015-10-02 US US14/874,318 patent/US9920027B2/en active Active
- 2015-10-28 JP JP2015211991A patent/JP6373818B2/ja active Active
-
2017
- 2017-08-10 JP JP2017155657A patent/JP6448726B2/ja active Active
-
2018
- 2018-02-02 US US15/887,838 patent/US10385037B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009010082A (es) | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. | |
MX2009003038A (es) | Derivados de quinazolinona 5-sustituidos como agentes antitumorales. | |
TW200745078A (en) | Isoindole-imide compounds and compositions comprising and methods of using the same | |
PH12014501082B1 (en) | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | |
MX2009002666A (es) | Compuestos de n-metilaminometil isoindol, composiciones que los comprenden y metodos que utilizan los mismos. | |
MY157495A (en) | 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same | |
MX2011011136A (es) | Eteres diarilicos. | |
WO2008027542A3 (en) | 5-substituted isoindoline compounds | |
RS20090036A (en) | Pyrazole derivatives as cytochrom p450 inhibitors | |
GEP20125456B (en) | Azetidines as mek inhibitors for the treatment of proliferative diseases | |
MX346608B (es) | Compuestos de isoindol 5-sustituidos. | |
MX2010003155A (es) | Derivados de ciclopropil aril amida y uso de los mismos. | |
MX2009006334A (es) | Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona. | |
MX2012007217A (es) | Derivados de (metilsulfonil) etilbenceno isoindolina y sus usos terapeuticos. | |
TNSN08369A1 (en) | Benzimidazole derivatives | |
MX2010006108A (es) | Inhibidores de estearoil-coa-desaturasa. | |
TW200738625A (en) | 3-Amino-1-arylpropyl indoles and aza-substituted indoles | |
IL188927A0 (en) | Aryloxy quinolines and uses thereof as 5-ht6 modulators | |
MX2009001572A (es) | Derivados de arilpiperazina y usos de los mismos. | |
IL194390A0 (en) | Heterocyclic gaba alpha subtype selective receptor modulators | |
MX2010008778A (es) | Derivados de 3-alquil-piperazina y usos de la misma. | |
UA94759C2 (ru) | Производные пиразола как ингибиторы цитохрома p450 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |